Belite Bio, Inc (BLTE)
Last Price$68.62.5%
Market Cap$2,075.9M
BLTE Rating
BLTE Quality rating performance
BLTE Intrinsic Value
Key Highlights:
As of Mar 11, 2025 BLTE Relative Value is $15.8, which is overvalued by 77.0%, compared to current share price of $68.6.
As of Mar 11, 2025 BLTE DCF Value is N/A, which is undervalued by N/A, compared to current share price of $68.6.
BLTE Share Price History
1W 14.7%
1M 20.2%
6M 40.9%
YTD 60.5%
1Y 53.8%
3Y 547.9%
5Y 547.9%
10Y 547.9%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
BLTE Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$2,075.9M
$2,075.9M
$0.0
Shares Outstanding
30M
Employees
N/A
Growth (CAGR)
N/A
N/A
(1.51%)
Profitability
Intrinsic Value
$16.0 (76.6% overvalued)
N/A
$16.0
($5.2)
(100.0%)
(38.7%)
Valuation (LTM)
Return on Capital
Financial Health
Dividends
Earnings
Jan 01, 1970
MISS by 0.0%
BEAT by (7.1%)
(6.7%)
4 Beat & 6 Miss
BLTE Stock Financials
BLTE Income Statement Metrics
Annual
Quarterly
LTM
BLTE Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($29.8M) -100.0% YoY
Capital Expenditure (CAPEX)
($63.0K) -100.0% YoY
Free Cash Flow (FCF)
($29.9M) -100.0% YoY
BLTE Income Statement Overview
Annual
Quarterly
LTM
Dec'20
Dec'21
Dec'22
Dec'23
BLTE Balance Sheet Overview
Annual
Quarterly
LTM
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$94.6M
Current assets ($89.9M, 95.0% of total)
$88.2M (93.1%)
$867.0K (0.9%)
Other current assets
$916.0K (1.0%)
Non-current assets ($4,702.0K, 5.0% of total)
$0.0 (0.0%)
$1,301.0K (1.4%)
$3,235.0K (3.4%)
Other non-current assets
$166.0K (0.2%)
Financial position
($87.3M)
Cash & Short-term
Investments
Total Debt
BLTE Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
BLTE Earnings Surprises
Crunching data... Almost there!
BLTE Dividends
BLTE Dividend Yield
Crunching data... Almost there!
BLTE Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with BLTE
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$2,075.9M | 5.3 | $16.0 76.6% overvalued | 53.8% | $0.0 | $0.0 | N/A | N/A | N/A | N/A | 0.0% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Belite Bio, Inc (BLTE) stock rating?
As of today, Belite Bio, Inc has a stock rating of 5 (out of 10), which is considered Good.
is Belite Bio, Inc (BLTE) a good stock to buy?
As of today, Belite Bio, Inc has a Good stock rating, which is 76.6% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.